Will Your Insurance Actually Cover
Your GLP-1 Drug?

How to Use This Screener

The GLP-1 Insurance Eligibility Screener does what no insurance company website makes easy: it tells you plainly whether your specific combination of drug, diagnosis, insurer, and employer is likely to result in prior authorization approval — and exactly what to do whether the answer is yes, maybe, or no. Unlike the gated coverage checkers offered by Ro and WeightWatchers, this tool requires no email address and produces results for your specific insurer rather than generic estimates.

Question 1 — Drug selection matters more than most patients realize. Ozempic and Mounjaro carry a Type 2 diabetes FDA indication, which means insurers route them through diabetes formulary criteria where coverage is considerably stronger. Wegovy and Zepbound carry weight-loss indications, which face separate, often stricter, prior authorization criteria. If you have Type 2 diabetes, your prescriber may be able to prescribe Ozempic or Mounjaro for your diabetes management even when your primary goal is weight loss — this is a legitimate and commonly used coverage strategy worth discussing with your physician.

Question 2 — BMI is the primary clinical gate for virtually every insurer's GLP-1 coverage criteria. A BMI of 30 or above meets the baseline obesity threshold. A BMI of 27 to 29.9 requires at least one qualifying comorbidity to meet coverage criteria. A BMI below 27 will be denied by almost all commercial insurers for weight-loss indications regardless of other factors. Enter your actual height and weight — the calculator converts to BMI automatically.

Questions 3 through 5 capture your diagnosis, insurer, and employer size. These three factors together determine whether your employer's specific plan has elected to cover GLP-1 drugs for weight management — a decision that varies enormously. The KFF 2025 Employer Health Benefits Survey found that 43% of employers with 5,000 or more employees now cover GLP-1s for weight loss, compared to just 15% of employers with fewer than 200 workers. Your insurer sets the clinical criteria; your employer decides whether the benefit is included at all.

Understanding Your Coverage Score

The likelihood score shown after calculation is a composite estimate based on your specific combination of inputs, calibrated against publicly available 2026 prior authorization policies from each major insurer. A score of 75% or above indicates your profile meets the core clinical criteria and your insurer's plan design is generally favorable — you are a strong prior authorization candidate. A score of 40 to 74% indicates a mixed picture: you may meet clinical criteria but face coverage exclusions at the plan level, or your diagnosis is borderline for the insurer's threshold. A score below 40% indicates significant coverage barriers that will require active steps — an appeal, a prescriber strategy change, or exploring alternative payment options — to overcome.

The score does not account for one critical factor: whether your specific employer has elected to include GLP-1 drug coverage in their benefit design. Insurers like UnitedHealthcare, Aetna, and Cigna all offer coverage as an optional employer add-on — meaning two employees at different companies with the exact same insurer may have completely different coverage outcomes. The only definitive way to confirm this is to call the member services number on the back of your insurance card and ask specifically: "Does my plan cover GLP-1 medications for obesity or weight management under the pharmacy benefit?"

What Your Insurer Actually Requires in 2026

UnitedHealthcare (OptumRx)

UHC covers Ozempic and Mounjaro for Type 2 diabetes on most commercial plans with prior authorization. Weight-loss indications (Wegovy, Zepbound) require the employer to have elected weight-loss medication coverage — approximately 43% of large employer UHC plans include it. When covered, UHC typically requires BMI 30+ or 27+ with comorbidity, documentation of a structured weight management program attempt, and reauthorization every 12 months demonstrating at least 5% body weight loss.

Aetna / CVS Health

Aetna's commercial plans cover GLP-1s for weight management when the employer has elected the benefit. ACA marketplace plans through Aetna cover weight-loss GLP-1s; the self-funded AFA (Aetna Funding Advantage) plans do not. Aetna's 2026 criteria include BMI 30+ or 27+ with qualifying comorbidity, and — for Anthem/BCBS plans using the Vida health program — active engagement with the lifestyle modification program as a condition of continued coverage.

Cigna

Cigna's March 2026 formulary policy specifically excludes weight-loss GLP-1s from many benefit plans, making it one of the more restrictive commercial insurers. When coverage is available, Cigna applies strict BMI criteria, requires documentation of behavioral and dietary modification attempts, and sets a body-weight loss benchmark (typically 5% by month 8) as a condition for continuation approval. Patients with Type 2 diabetes have considerably better coverage odds through the diabetes formulary pathway.

BCBS

Blue Cross Blue Shield is 36 independent regional plans, not a single insurer — coverage varies significantly by geography. BCBS of Texas and BCBS of Alabama, for example, have different formularies than BCBS of Massachusetts or BCBS of California. As a general benchmark, large-group BCBS commercial plans have been expanding GLP-1 weight-loss coverage in 2025 and 2026, but you must verify with your specific regional plan.

Medicare Part D (2026)

Starting January 2026, Medicare Part D covers GLP-1 drugs for obesity for the first time — a significant policy change affecting an estimated 30 million eligible beneficiaries. Coverage requires BMI 30+ or BMI 27+ with a qualifying comorbidity, and the drug must be on your specific Part D plan's formulary. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, most eligible beneficiaries pay $50 to $100 per month. Manufacturer savings cards cannot be combined with Medicare.

What to Do If You Are Denied

A prior authorization denial is not a final answer. Studies consistently show that 65% or more of initial GLP-1 prior authorization denials are overturned on appeal when the appeal includes proper clinical documentation. The most effective appeals contain: a letter of medical necessity from your prescriber explaining why a GLP-1 is clinically appropriate for your specific condition; documentation of previous weight management attempts including diet programs, exercise regimens, or other medications; your most recent lab results showing relevant metabolic markers; and a request for a peer-to-peer review between your prescriber and the insurer's medical director.

The peer-to-peer review — a direct conversation between your doctor and the insurer's reviewing physician — overturns more denials than written appeals alone. Ask your prescriber's office specifically for a "peer-to-peer review request" rather than a standard appeal, and make sure your prescriber's clinical notes explicitly address the insurer's stated denial reason. If the internal appeal is denied, you have the right to an external independent review in most states — ask your insurer for instructions on requesting one.

If coverage remains out of reach after exhausting appeals, use our True Monthly Cost Calculator to see manufacturer savings programs and compounded alternatives that can bring your monthly cost to $99–$349 without insurance, and our HSA/FSA Tax Savings Calculator to apply a pre-tax discount on whatever option you choose.

Sources: UnitedHealthcare OptumRx Clinical Coverage Guidelines 2026, Cigna Weight Loss GLP-1 PA Policy March 2026, Aetna GLP-1 Benefit Coverage documentation, AHIP voluntary PA commitments effective January 2026, KFF 2025 Employer Health Benefits Survey, CMS Medicare Part D GLP-1 coverage guidance 2026, Honest Care GLP-1 Insurance Coverage Guide. Coverage criteria change frequently — verify current requirements directly with your insurer before submitting a prior authorization request. This content is for informational purposes only and does not constitute insurance or medical advice.